ZURICH (Reuters) -Switzerland’s Roche on Friday pointed to the fact that one of its U.S. units broke ground on a new facility in August and that the pharma company had pledged major U.S. investments after President Donald Trump’s latest tariff announcement.

Trump said on Thursday the United States will impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a pharmaceutical company is building a manufacturing plant in the U.S.

A Roche spokesperson pointed to the August 25 announcement about its Genentech unit’s plans for the facility in Holly Springs, North Carolina as well as Roche’s $50 billion pledge to invest in U.S. manufacturing and research and development.

Roche and Novartis are Switzerland’s two biggest pharmaceutical companies with

See Full Page